TABLE 3.
Statistical analysis of dopamine receptor agonist treatment and mitochondrial respiration.
| Assay/mouse line | Sex | Three-way ANOVA factors | |||
|---|---|---|---|---|---|
| Genotype | Interval | Treatment | Interaction | ||
| D1 agonist SKF-81297 | Males | F (1, 18) = 8.890, p = 0.0080 | F (2.710, 48.78) = 14.01, p < 0.0001 | F (1, 18) = 32.14, p < 0.0001 | Interval X treatment |
| F (6, 108) = 6.509, p < 0.0001 | |||||
| Bmal1 | Females | F (1, 12) = 5.213, p = 0.0414 | F (2.272, 27.26) = 3.229, p = 0.0495 | n.s. | Interval X genotype |
| F (6, 72) = 2.719, p = 0.0195 | |||||
| D2 agonist Quinpirole | Males | n.s. | F (3.106, 55.92) = 104.7, p < 0.0001 | F (1, 18) = 88.74, p < 0.0001 | Interval X treatment |
| F (6, 108) = 8.006, p < 0.0001 | |||||
| Bmal1 | Females | F (1, 11) = 5.461, p = 0.0394 | F (3.208, 35.28) = 47.70, p < 0.0001 | F (1, 11) = 10.83, p = 0.0072 | Interval X treatment |
| F (6, 66) = 6.584, p < 0.0001 | |||||
| D1 agonist SKF-81297 | Males | n.s. | F (1.918, 26.85) = 6.800, p = 0.0045 | F (1, 14) = 11.37, p = 0.0046 | Interval X treatment |
| F (6, 84) = 3.481, p = 0.0040 | |||||
| Gpr88 | Females | n.s. | F (2.470, 51.86) = 9.164, p = 0.0002 | F (1, 21) = 6.176, p = 0.0215 | Interval X treatment |
| F (6, 126) = 2.713, p = 0.0164 | |||||
| D2 agonist Quinpirole | Males | n.s. | F (3.727, 55.91) = 145.3, p < 0.0001 | F (1, 15) = 35.34, p < 0.0001 | Interval X treatment |
| F (6, 90) = 9.159, p < 0.0001 | |||||
| Interval X genotype | |||||
| F (6, 84) = 3.242, p = 0.0065 | |||||
| Interval X treatment | |||||
| F (6, 84) = 6.930, p < 0.0001 | |||||
| Gpr88 | Females | n.s. | F (3.239, 45.34) = 86.79, p < 0.0001 | F (1, 14) = 86.72, p < 0.0001 | |
| Mitochondrial respiration | Males | n.s. | n.s. | F (7, 64) = 176.5, p < 0.0001 | n.s. |
| Bmal1 | Females | n.s. | n.s. | F (7, 64) = 174.8, p < 0.0001 | n.s. |
| Mitochondrial respiration | Males | n.s. | n.s. | F (7, 32) = 34.32, p < 0.0001 | n.s. |
| Gpr88 | Females | n.s. | n.s. | F (7, 32) = 17.20, p < 0.0001 | n.s. |